- Home
- AVIR vs FDMT Comparison
AVIR vs FDMT Comparison
Compare AVIR & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVIR | FDMT |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 434.5M | 449.6M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AVIR | FDMT |
|---|---|---|
| Price | $4.27 | $8.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $10.00 | ★ $31.71 |
| AVG Volume (30 Days) | 318.7K | ★ 620.7K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.00 | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $351,367,000.00 | $85,209,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $2.78 | $3.68 |
| 52 Week High | $6.45 | $12.34 |
Technical Indicators
Market Signals| Indicator | AVIR | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 37.87 | 43.24 |
| Support Level | $4.04 | $8.39 |
| Resistance Level | $4.34 | $8.80 |
| Average True Range (ATR) | 0.22 | 0.69 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 31.94 | 23.11 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).